Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. C4 Therapeutics, Inc.
  6. News
  7. Summary
    CCCC   US12529R1077

C4 THERAPEUTICS, INC.

(CCCC)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
6.870 USD   +2.38%
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-Null Tumors
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb

01/10/2022 | 02:25pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
C4 THERAPEUTICS, INC. 2.38% 6.87 Delayed Quote.-78.66%
ON SEMICONDUCTOR CORPORATION 6.07% 58.5 Delayed Quote.-13.87%
All news about C4 THERAPEUTICS, INC.
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluat..
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
05/16C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CF..
GL
05/09HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy R..
MT
05/05C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
05/05C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/05C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highli..
GL
04/28Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Ris..
MT
04/18UBS Adjusts C4 Therapeutics Price Target to $26 From $64, Maintains Buy Rating
MT
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 35,0 M - -
Net income 2022 -141 M - -
Net cash 2022 221 M - -
P/E ratio 2022 -2,49x
Yield 2022 -
Capitalization 335 M 335 M -
EV / Sales 2022 3,25x
EV / Sales 2023 3,92x
Nbr of Employees 121
Free-Float 86,9%
Chart C4 THERAPEUTICS, INC.
Duration : Period :
C4 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C4 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 6,87 $
Average target price 25,67 $
Spread / Average Target 274%
EPS Revisions
Managers and Directors
Andrew J. Hirsch President, Chief Executive Officer & Director
Lauren A. White Treasurer, Chief Financial & Accounting Officer
Marc A. Cohen Executive Chairman
Adam S. Crystal Chief Medical Officer
Stewart Fisher Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
C4 THERAPEUTICS, INC.-78.66%335
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002